MX350539B - Compuestos de enediino, conjugados de los mismos y sus usos y metodos. - Google Patents
Compuestos de enediino, conjugados de los mismos y sus usos y metodos.Info
- Publication number
- MX350539B MX350539B MX2014009234A MX2014009234A MX350539B MX 350539 B MX350539 B MX 350539B MX 2014009234 A MX2014009234 A MX 2014009234A MX 2014009234 A MX2014009234 A MX 2014009234A MX 350539 B MX350539 B MX 350539B
- Authority
- MX
- Mexico
- Prior art keywords
- conjugates
- methods therefor
- enediyne compounds
- enediyne
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261598143P | 2012-02-13 | 2012-02-13 | |
| US201261653785P | 2012-05-31 | 2012-05-31 | |
| PCT/US2013/025247 WO2013122823A1 (en) | 2012-02-13 | 2013-02-08 | Enediyne compounds, conjugates thereof, and uses and methods therefor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014009234A MX2014009234A (es) | 2014-11-10 |
| MX350539B true MX350539B (es) | 2017-09-08 |
Family
ID=47722570
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014009234A MX350539B (es) | 2012-02-13 | 2013-02-08 | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8709431B2 (OSRAM) |
| EP (1) | EP2814829B1 (OSRAM) |
| JP (1) | JP6113194B2 (OSRAM) |
| KR (1) | KR101660146B1 (OSRAM) |
| CN (1) | CN104220441B (OSRAM) |
| AR (1) | AR089972A1 (OSRAM) |
| AU (1) | AU2013221873B2 (OSRAM) |
| BR (1) | BR112014019990A8 (OSRAM) |
| CA (1) | CA2864420C (OSRAM) |
| CL (1) | CL2014002096A1 (OSRAM) |
| CO (1) | CO7061078A2 (OSRAM) |
| CY (1) | CY1118899T1 (OSRAM) |
| DK (1) | DK2814829T3 (OSRAM) |
| EA (1) | EA027925B1 (OSRAM) |
| ES (1) | ES2615268T3 (OSRAM) |
| HK (1) | HK1204326A1 (OSRAM) |
| HR (1) | HRP20170334T1 (OSRAM) |
| HU (1) | HUE033704T2 (OSRAM) |
| IL (1) | IL233965B (OSRAM) |
| LT (1) | LT2814829T (OSRAM) |
| MX (1) | MX350539B (OSRAM) |
| PE (1) | PE20141791A1 (OSRAM) |
| PL (1) | PL2814829T3 (OSRAM) |
| PT (1) | PT2814829T (OSRAM) |
| RS (1) | RS55763B1 (OSRAM) |
| SG (1) | SG11201404667XA (OSRAM) |
| SI (1) | SI2814829T1 (OSRAM) |
| SM (1) | SMT201700137T1 (OSRAM) |
| TW (1) | TW201336851A (OSRAM) |
| WO (1) | WO2013122823A1 (OSRAM) |
| ZA (1) | ZA201406723B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3407B1 (ar) | 2012-05-31 | 2019-10-20 | Eisai R&D Man Co Ltd | مركبات رباعي هيدرو بيرازولو بيريميدين |
| EA201690388A1 (ru) * | 2013-08-14 | 2016-07-29 | Уильям Марш Райс Юниверсити | Новые производные унциаламицина, способы их синтеза и их применение в качестве противоопухолевых агентов |
| US10450363B2 (en) | 2014-03-20 | 2019-10-22 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
| WO2016081746A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| ES2807182T3 (es) | 2014-11-21 | 2021-02-22 | Bristol Myers Squibb Co | Anticuerpos frente a CD73 y sus usos |
| EA037590B1 (ru) | 2014-11-25 | 2021-04-19 | Бристол-Майерс Сквибб Компани | Связывающиеся с pd-l1 полипептиды на основе 10fn3 домена для визуализации |
| US10336766B2 (en) * | 2015-01-08 | 2019-07-02 | The Scripps Research Institute | Anticancer drug candidates |
| WO2016144608A1 (en) | 2015-03-10 | 2016-09-15 | Bristol-Myers Squibb Company | Antibodies conjugatable by transglutaminase and conjugates made therefrom |
| RS63897B1 (sr) | 2015-05-29 | 2023-02-28 | Bristol Myers Squibb Co | Antitela protiv ox40 i njihova primena |
| KR102818445B1 (ko) | 2015-09-23 | 2025-06-10 | 브리스톨-마이어스 스큅 컴퍼니 | 글리피칸-3-결합 피브로넥틴 기반 스캐폴드 분자 |
| US10233212B2 (en) | 2015-11-03 | 2019-03-19 | Industrial Technology Research Institute | Compounds, linker-drugs and ligand-drug conjugates |
| JP2019505575A (ja) | 2015-12-21 | 2019-02-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 部位特異的な結合のための変異型抗体 |
| SG10201913033UA (en) | 2016-03-04 | 2020-03-30 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| CN106267188B (zh) * | 2016-08-15 | 2025-06-17 | 深圳大学 | 小分子免疫激动剂偶联pd-1抗体的新型抗体及其在抗肿瘤中的应用 |
| WO2018048975A1 (en) | 2016-09-09 | 2018-03-15 | Bristol-Myers Squibb Company | Use of an anti-pd-1 antibody in combination with an anti-mesothelin antibody in cancer treatment |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| EP3630833A1 (en) | 2017-05-25 | 2020-04-08 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| WO2019110725A1 (en) * | 2017-12-06 | 2019-06-13 | Synaffix B.V. | Enediyne conjugates |
| CN110183659B (zh) * | 2018-02-21 | 2022-04-26 | 香港科技大学 | 含有杂环的聚合物、其制备方法及其应用 |
| EP3887397A1 (en) | 2018-11-28 | 2021-10-06 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| FI3886914T3 (fi) | 2018-11-30 | 2023-05-26 | Bristol Myers Squibb Co | Glutamiinin sisältävän kevytketjun c-terminaalisen jatkeen käsittävä vasta-aine, sen konjugaatteja, ja menetelmiä ja käyttöjä |
| KR20210102334A (ko) | 2018-12-12 | 2021-08-19 | 브리스톨-마이어스 스큅 컴퍼니 | 트랜스글루타미나제 접합을 위해 변형된 항체, 그의 접합체, 및 방법 및 용도 |
| WO2020237225A1 (en) * | 2019-05-22 | 2020-11-26 | Board Of Regents, The University Of Texas System | Functionalized gold carbene naphthoquinone complexes for use in the treatment of cancer |
| US20240377413A1 (en) | 2019-09-16 | 2024-11-14 | Bristol-Myers Squibb Company | Dual capture method for analysis of antibody-drug conjugates |
| BR112023026735A2 (pt) | 2021-06-28 | 2024-03-12 | Byondis Bv | Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4631190A (en) | 1981-06-26 | 1986-12-23 | Shen Wei C | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US5144011A (en) | 1981-06-26 | 1992-09-01 | Boston University | Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4698420A (en) | 1985-02-25 | 1987-10-06 | Xoma Corporation | Antibody hybrid molecules and process for their preparation |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5281710A (en) * | 1990-08-01 | 1994-01-25 | The Scripps Research Institute | Dynemicin analogs: synthesis, methods of preparation and use |
| US5162330A (en) * | 1990-11-05 | 1992-11-10 | Bristol-Myers Squibb Co. | Dynemicin c antibiotic, its triacetyl derivative and pharmaceutical composition containing same |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US6955811B2 (en) | 1997-11-07 | 2005-10-18 | Trillium Therapeutics Inc. | Methods of inhibiting immune response suppression by administering antibodies to OX-2 |
| WO2001014424A2 (en) | 1999-08-24 | 2001-03-01 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7087600B2 (en) | 2001-05-31 | 2006-08-08 | Medarex, Inc. | Peptidyl prodrugs and linkers and stabilizers useful therefor |
| US7091186B2 (en) | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
| KR100829283B1 (ko) | 2002-01-09 | 2008-05-13 | 메다렉스, 인코포레이티드 | Ｃｄ３０에 대한 인간 모노클로날 항체 |
| ES2340494T3 (es) | 2003-04-15 | 2010-06-04 | Glaxosmithkline Llc | Mutantes de sustitucion de il-18 humana y sus conjugados. |
| GT200400138A (es) | 2003-07-22 | 2005-03-22 | Anticuerpos rgi y uso de los mismos. | |
| WO2005051976A2 (en) | 2003-11-20 | 2005-06-09 | Ansata Therapeutics, Inc. | Protein and peptide ligation processes and one-step purification processes |
| US8170637B2 (en) * | 2008-05-06 | 2012-05-01 | Neurosky, Inc. | Dry electrode device and method of assembly |
| AU2005216251B2 (en) | 2004-02-23 | 2011-03-10 | Genentech, Inc. | Heterocyclic self-immolative linkers and conjugates |
| JP4806680B2 (ja) | 2004-05-19 | 2011-11-02 | メダレックス インコーポレイテッド | 自己犠牲リンカー及び薬剤複合体 |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| CN101065151B (zh) | 2004-09-23 | 2014-12-10 | 健泰科生物技术公司 | 半胱氨酸改造的抗体和偶联物 |
| US7714016B2 (en) | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| MX2007015944A (es) | 2005-06-20 | 2008-03-07 | Medarex Inc | Anticuerpos cd19 y sus usos. |
| CA2623236A1 (en) | 2005-09-26 | 2007-04-05 | Medarex, Inc. | Human monoclonal antibodies to cd70 |
| NZ566982A (en) | 2005-09-26 | 2011-06-30 | Medarex Inc | Duocarmycin drug conjugates |
| WO2007038868A2 (en) * | 2005-10-03 | 2007-04-12 | The University Of British Columbia | Novel enediyne compound and uses thereof |
| EP1940789B1 (en) | 2005-10-26 | 2011-11-23 | Medarex, Inc. | Methods and compounds for preparing cc-1065 analogs |
| CA2627190A1 (en) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Duocarmycin derivatives as novel cytotoxic compounds and conjugates |
| BRPI0620601A2 (pt) | 2005-12-08 | 2011-11-16 | Medarex Inc | anticorpo monoclonal humano isolado ou uma porção ligante ao antìgeno do mesmo, composição, imunoconjugado, molécula de ácido nucléico isolada, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-o8e e método para tratar ou prevenir uma doença definida pelo crescimento de células tumorais expressando o8e |
| EA017812B1 (ru) | 2005-12-08 | 2013-03-29 | Медарекс, Инк. | Выделенное моноклональное антитело или его антигенсвязывающий участок, которые связываются с протеинтирозинкиназой 7 ( ptk7) человека, и их применение |
| KR100869414B1 (ko) | 2005-12-13 | 2008-11-21 | 야마하 가부시키가이샤 | 건반식 음판 타악기용의 음판 및 그 제조방법, 음판타악기의 음원 유닛 및 건반식 타악기 |
| JP2010502221A (ja) | 2006-09-08 | 2010-01-28 | アンブルックス，インコーポレイテッド | 脊椎動物細胞による非天然アミノ酸の部位特異的組み込み |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| UY30776A1 (es) | 2006-12-21 | 2008-07-03 | Medarex Inc | Anticuerpos cd44 |
| TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
| AU2008218766A1 (en) | 2007-02-21 | 2008-08-28 | Medarex, Inc. | Chemical linkers with single amino acids and conjugates thereof |
| US8865875B2 (en) | 2007-08-22 | 2014-10-21 | Medarex, L.L.C. | Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions |
| BRPI0816014A8 (pt) | 2007-10-01 | 2018-06-19 | Bristol Myers Squibb Co | anticorpo humano monoclonal isolado, composição, conjugado anticorpo-molécula parceiro, mólecula isolada de ácido nucléico, vetor de expressão, célula hospedeira, método para preparar um anticorpo anti-mesotelina, método de inibição do crescimento de uma célula tumoral expressando a mesotelina, método de tratamento do câncer em um indivíduo, anticorpo anti-mesotelina isolado, e método de inibir o crescimento de uma célula expressando a mesotelina |
| WO2010087994A2 (en) | 2009-01-30 | 2010-08-05 | Whitehead Institute For Biomedical Research | Methods for ligation and uses thereof |
-
2013
- 2013-02-08 MX MX2014009234A patent/MX350539B/es active IP Right Grant
- 2013-02-08 HR HRP20170334TT patent/HRP20170334T1/hr unknown
- 2013-02-08 CA CA2864420A patent/CA2864420C/en not_active Expired - Fee Related
- 2013-02-08 EA EA201491447A patent/EA027925B1/ru not_active IP Right Cessation
- 2013-02-08 DK DK13704871.6T patent/DK2814829T3/en active
- 2013-02-08 TW TW102105196A patent/TW201336851A/zh unknown
- 2013-02-08 HK HK15104893.3A patent/HK1204326A1/xx unknown
- 2013-02-08 HU HUE13704871A patent/HUE033704T2/en unknown
- 2013-02-08 AR ARP130100431A patent/AR089972A1/es unknown
- 2013-02-08 KR KR1020147025070A patent/KR101660146B1/ko not_active Expired - Fee Related
- 2013-02-08 JP JP2014556700A patent/JP6113194B2/ja not_active Expired - Fee Related
- 2013-02-08 RS RS20170239A patent/RS55763B1/sr unknown
- 2013-02-08 EP EP13704871.6A patent/EP2814829B1/en active Active
- 2013-02-08 CN CN201380019853.3A patent/CN104220441B/zh not_active Expired - Fee Related
- 2013-02-08 LT LTEP13704871.6T patent/LT2814829T/lt unknown
- 2013-02-08 SM SM20170137T patent/SMT201700137T1/it unknown
- 2013-02-08 PE PE2014001257A patent/PE20141791A1/es not_active Application Discontinuation
- 2013-02-08 SG SG11201404667XA patent/SG11201404667XA/en unknown
- 2013-02-08 BR BR112014019990A patent/BR112014019990A8/pt not_active Application Discontinuation
- 2013-02-08 PL PL13704871T patent/PL2814829T3/pl unknown
- 2013-02-08 SI SI201330469T patent/SI2814829T1/sl unknown
- 2013-02-08 WO PCT/US2013/025247 patent/WO2013122823A1/en not_active Ceased
- 2013-02-08 AU AU2013221873A patent/AU2013221873B2/en not_active Ceased
- 2013-02-08 ES ES13704871.6T patent/ES2615268T3/es active Active
- 2013-02-08 PT PT137048716T patent/PT2814829T/pt unknown
- 2013-02-11 US US13/764,226 patent/US8709431B2/en active Active
-
2014
- 2014-03-10 US US14/203,118 patent/US9156850B2/en active Active
- 2014-08-06 IL IL233965A patent/IL233965B/en active IP Right Grant
- 2014-08-07 CL CL2014002096A patent/CL2014002096A1/es unknown
- 2014-08-28 CO CO14189746A patent/CO7061078A2/es unknown
- 2014-09-12 ZA ZA2014/06723A patent/ZA201406723B/en unknown
-
2017
- 2017-03-03 CY CY20171100285T patent/CY1118899T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX350539B (es) | Compuestos de enediino, conjugados de los mismos y sus usos y metodos. | |
| EA030199B9 (ru) | Терапевтически активные соединения и способы их применения | |
| MX340090B (es) | Analogos de spliceostatina. | |
| NZ749217A (en) | Androgen receptor modulator and uses thereof | |
| NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
| GB201209613D0 (en) | New compounds | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
| IN2014DN05986A (OSRAM) | ||
| MX2015011897A (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| IN2015DN01163A (OSRAM) | ||
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| GB201106743D0 (en) | Novel compounds | |
| MX2015001720A (es) | Hetero-azepinonas sustituidas. | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
| IN2014DN06104A (OSRAM) | ||
| PH12015501088A1 (en) | Dimeric compounds | |
| PH12015501038A1 (en) | Inhibitors of iap | |
| MX349373B (es) | Nuevos derivados de pirazina. | |
| WO2015040243A3 (en) | Methods and compositions for targeting tumor microenvironment and for preventing metastasis | |
| PH12015500399A1 (en) | Azaindolines | |
| MX2018004696A (es) | Analogos de epotilona, metodos de sintesis, metodos de tratamiento y conjugados con farmacos de los mismos. | |
| MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |